~~<i id='1837792D11'><strike id='1837792D11'><tt id='1837792D11'><pre id='1837792D11'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-09-30 05:25:29 Page View：2

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Health care court cases: Humana, Sutter, Novant
Next article： Medicare details structure of new drug price negotiation program

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

CTscansshowedthatthepatientinitiallyrespondedtolorlatinib(left).Buteightmonthslater,themetastaticliv

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

'The View' co

5:21BillGeddie.HeidiGutman/ABCBillGeddie,thetelevisionproducerwhoco-foundedABC's"TheView&q